E
Kraig Biocraft Laboratories, Inc.
KBLB
$0.0871
$0.00364.31%
E
Sell
8/21/2024Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 8/21/2024 due to a substantial decline in the growth index, solvency index and valuation index. EBIT declined 231.2% from -$448.7 to -$1.49M, earnings per share declined from -$0.0005 to -$0.0015, and the quick ratio declined from 0.23 to 0.17.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 8/21/2024 due to a substantial decline in the growth index, solvency index and valuation index. EBIT declined 231.2% from -$448.7 to -$1.49M, earnings per share declined from -$0.0005 to -$0.0015, and the quick ratio declined from 0.23 to 0.17.
D
Sell
2/6/2024Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 2/6/2024 due to a noticeable increase in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 2/6/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D on 03/14/2023.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from E+ on 02/09/2023.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D on 02/08/2023.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D on 02/08/2023.
D
Sell
1/24/2023Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index and total return index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index and total return index.
D
Sell
11/23/2022Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 11/23/2022 due to a large increase in the growth index and solvency index. Earnings per share increased from -$0.0011 to -$0.0008, and EBIT increased 2.12% from -$536.7 to -$525.3.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 11/23/2022 due to a large increase in the growth index and solvency index. Earnings per share increased from -$0.0011 to -$0.0008, and EBIT increased 2.12% from -$536.7 to -$525.3.
E
Sell
11/21/2022Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 11/21/2022 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 11/21/2022 due to a decline in the total return index and volatility index.
D
Sell
11/4/2022Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 11/4/2022 due to an increase in the volatility index, total return index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 11/4/2022 due to an increase in the volatility index, total return index and valuation index.
E
Sell
10/19/2022Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 10/19/2022 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 10/19/2022 due to a decline in the total return index and volatility index.
D
Sell
8/2/2022Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 8/2/2022 due to an increase in the growth index, solvency index and volatility index. Debt to equity declined from -0.29 to -0.34, the quick ratio increased from 0.46 to 0.53, and EBIT increased 1.65% from -$545.7 to -$536.7.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 8/2/2022 due to an increase in the growth index, solvency index and volatility index. Debt to equity declined from -0.29 to -0.34, the quick ratio increased from 0.46 to 0.53, and EBIT increased 1.65% from -$545.7 to -$536.7.
E
Sell
7/26/2022Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 7/26/2022 due to a decline in the volatility index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 7/26/2022 due to a decline in the volatility index and valuation index.
D
Sell
7/8/2022Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 7/8/2022 due to an increase in the volatility index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 7/8/2022 due to an increase in the volatility index and valuation index.
E
Sell
6/21/2022Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 6/21/2022 due to a decline in the total return index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 6/21/2022 due to a decline in the total return index.
D
Sell
5/31/2022Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 05/31/2022.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index and total return index. Operating cash flow declined 21.28% from -$395.2 to -$479.3, and EBIT declined 5.59% from -$516.8 to -$545.7.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index and total return index. Operating cash flow declined 21.28% from -$395.2 to -$479.3, and EBIT declined 5.59% from -$516.8 to -$545.7.
D
Sell
5/5/2022Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
4/20/2022Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and valuation index.
E
Sell
11/8/2021Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D on 11/8/2021 due to a large decline in the solvency index, valuation index and volatility index. The quick ratio declined from 0.42 to 0.3.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to E+ from D on 11/8/2021 due to a large decline in the solvency index, valuation index and volatility index. The quick ratio declined from 0.42 to 0.3.
D
Sell
8/18/2021Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 8/18/2021 due to a major increase in the solvency index and valuation index. The quick ratio increased from 0.12 to 0.42, and debt to equity declined from -0.19 to -0.3.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 8/18/2021 due to a major increase in the solvency index and valuation index. The quick ratio increased from 0.12 to 0.42, and debt to equity declined from -0.19 to -0.3.
D
Sell
8/4/2021Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D- from D on 8/4/2021 due to a large decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D- from D on 8/4/2021 due to a large decline in the total return index and volatility index.
D
Sell
5/12/2021Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 5/12/2021 due to a major increase in the growth index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 5/12/2021 due to a major increase in the growth index and volatility index.
D
Sell
6/17/2020Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D- from D on 6/17/2020 due to a large decline in the total return index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D- from D on 6/17/2020 due to a large decline in the total return index and valuation index.
D
Sell
5/26/2020Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 5/26/2020 due to a large increase in the total return index and valuation index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D from D- on 5/26/2020 due to a large increase in the total return index and valuation index.
D
Sell
5/1/2020Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index.
D
Sell
4/22/2020Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 4/22/2020 due to a significant decline in the solvency index, volatility index and growth index. EBIT declined 262.52% from -$817.8 to -$2.96M, earnings per share declined from -$0.0011 to -$0.0036, and the quick ratio declined from 0.02 to 0.01.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 4/22/2020 due to a significant decline in the solvency index, volatility index and growth index. EBIT declined 262.52% from -$817.8 to -$2.96M, earnings per share declined from -$0.0011 to -$0.0036, and the quick ratio declined from 0.02 to 0.01.
D
Sell
4/8/2020Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D+ from D on 4/8/2020 due to an increase in the growth index, total return index and solvency index. EBIT increased 22.62% from -$1.06M to -$817.8, earnings per share increased from -$0.0013 to -$0.0011, and debt to equity declined from -0.08 to -0.09.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D+ from D on 4/8/2020 due to an increase in the growth index, total return index and solvency index. EBIT increased 22.62% from -$1.06M to -$817.8, earnings per share increased from -$0.0013 to -$0.0011, and debt to equity declined from -0.08 to -0.09.
D
Sell
2/12/2020Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 2/12/2020 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 2/12/2020 due to a decline in the total return index and volatility index.
D
Sell
1/21/2020Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D+ from D on 1/21/2020 due to an increase in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D+ from D on 1/21/2020 due to an increase in the total return index and volatility index.
D
Sell
12/30/2019Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 12/30/2019 due to a major decline in the total return index, growth index and volatility index. EBIT declined 215.3% from -$335.2 to -$1.06M, earnings per share declined from -$0.0005 to -$0.0013, and operating cash flow declined 36.33% from -$230.4 to -$314.1.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 12/30/2019 due to a major decline in the total return index, growth index and volatility index. EBIT declined 215.3% from -$335.2 to -$1.06M, earnings per share declined from -$0.0005 to -$0.0013, and operating cash flow declined 36.33% from -$230.4 to -$314.1.
D
Sell
8/14/2019Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C on 8/14/2019 due to a significant decline in the growth index. Operating cash flow declined 2.4% from -$225 to -$230.4.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C on 8/14/2019 due to a significant decline in the growth index. Operating cash flow declined 2.4% from -$225 to -$230.4.
C
Hold
2/26/2019Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 2/26/2019 due to a large increase in the total return index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 2/26/2019 due to a large increase in the total return index.
C
Hold
2/11/2019Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 2/11/2019 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0002 to -$0.0003, and total revenue declined 7.49% from $152.2 to $140.8.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 2/11/2019 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0002 to -$0.0003, and total revenue declined 7.49% from $152.2 to $140.8.
C
Hold
5/11/2018Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 5/11/2018 due to a noticeable increase in the growth index. Total revenue increased 54.92% from $70.1 to $108.6, earnings per share increased from -$0.0004 to -$0.0003, and EBIT increased 9.76% from -$251.1 to -$226.6.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 5/11/2018 due to a noticeable increase in the growth index. Total revenue increased 54.92% from $70.1 to $108.6, earnings per share increased from -$0.0004 to -$0.0003, and EBIT increased 9.76% from -$251.1 to -$226.6.
C
Hold
4/9/2018Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 4/9/2018 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 4/9/2018 due to a decline in the total return index and volatility index.
C
Hold
3/23/2018Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 3/23/2018 due to an increase in the growth index, total return index and volatility index. Total revenue increased 157.72% from $27.2 to $70.1, and operating cash flow increased 46.89% from -$149.3 to -$79.3.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 3/23/2018 due to an increase in the growth index, total return index and volatility index. Total revenue increased 157.72% from $27.2 to $70.1, and operating cash flow increased 46.89% from -$149.3 to -$79.3.
C
Hold
1/23/2018Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 1/23/2018 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 1/23/2018 due to a decline in the total return index and volatility index.
C
Hold
11/16/2017Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from D+ on 11/16/2017 due to a major increase in the growth index and volatility index. Earnings per share increased from -$0.0016 to -$0.0003, EBIT increased 80.72% from -$1.22M to -$234.4, and operating cash flow increased 51.42% from -$307.3 to -$149.3.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from D+ on 11/16/2017 due to a major increase in the growth index and volatility index. Earnings per share increased from -$0.0016 to -$0.0003, EBIT increased 80.72% from -$1.22M to -$234.4, and operating cash flow increased 51.42% from -$307.3 to -$149.3.
D
Sell
8/16/2017Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C- on 8/16/2017 due to a substantial decline in the total return index and growth index. EBIT declined 167.55% from -$454.5 to -$1.22M, earnings per share declined from -$0.0006 to -$0.0016, and operating cash flow declined 58.73% from -$193.6 to -$307.3.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C- on 8/16/2017 due to a substantial decline in the total return index and growth index. EBIT declined 167.55% from -$454.5 to -$1.22M, earnings per share declined from -$0.0006 to -$0.0016, and operating cash flow declined 58.73% from -$193.6 to -$307.3.
C
Hold
5/12/2017Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 5/12/2017 due to a decline in the growth index, volatility index and valuation index. Operating cash flow declined 3.47% from -$187.1 to -$193.6.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 5/12/2017 due to a decline in the growth index, volatility index and valuation index. Operating cash flow declined 3.47% from -$187.1 to -$193.6.
C
Hold
3/23/2017Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from D+ on 3/23/2017 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.0015 to -$0.0012, EBIT increased 19.4% from -$1.09M to -$877.8, and operating cash flow increased 14.37% from -$218.5 to -$187.1.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from D+ on 3/23/2017 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.0015 to -$0.0012, EBIT increased 19.4% from -$1.09M to -$877.8, and operating cash flow increased 14.37% from -$218.5 to -$187.1.
D
Sell
11/17/2016Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C- on 11/17/2016 due to a decline in the total return index and growth index. EBIT declined 117.52% from -$500.7 to -$1.09M, and earnings per share declined from -$0.0007 to -$0.0015.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C- on 11/17/2016 due to a decline in the total return index and growth index. EBIT declined 117.52% from -$500.7 to -$1.09M, and earnings per share declined from -$0.0007 to -$0.0015.
C
Hold
9/2/2016Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C- from D+ on 9/2/2016 due to a major increase in the total return index, growth index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C- from D+ on 9/2/2016 due to a major increase in the total return index, growth index and volatility index.
D
Sell
8/2/2016Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D+ from D on 8/2/2016 due to a noticeable increase in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to D+ from D on 8/2/2016 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/24/2016Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 3/24/2016 due to a decline in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 3/24/2016 due to a decline in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C on 3/11/2016 due to a major decline in the volatility index and total return index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C on 3/11/2016 due to a major decline in the volatility index and total return index.
C
Hold
11/6/2015Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 11/6/2015 due to a major increase in the growth index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 11/6/2015 due to a major increase in the growth index.
C
Hold
8/12/2015Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 8/12/2015 due to a large decline in the volatility index, growth index and solvency index. The quick ratio declined from 0.13 to 0.05.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 8/12/2015 due to a large decline in the volatility index, growth index and solvency index. The quick ratio declined from 0.13 to 0.05.
C
Hold
5/19/2015Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 5/19/2015 due to a substantial increase in the volatility index, growth index and efficiency index. Total capital increased 28.02% from -$1.23M to -$1.57M, and operating cash flow increased 9.32% from -$188.9 to -$206.5.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 5/19/2015 due to a substantial increase in the volatility index, growth index and efficiency index. Total capital increased 28.02% from -$1.23M to -$1.57M, and operating cash flow increased 9.32% from -$188.9 to -$206.5.
C
Hold
10/24/2014Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C- from D on 10/24/2014 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.35 to 0.46.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C- from D on 10/24/2014 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.35 to 0.46.
D
Sell
8/21/2014Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 8/21/2014 due to a decline in the volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D from D+ on 8/21/2014 due to a decline in the volatility index.
D
Sell
8/20/2014Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C on 8/20/2014 due to a significant decline in the efficiency index, growth index and volatility index. EBIT declined 16.35% from -$652.4 to -$545.7, net income declined 13.27% from -$650.3 to -$564, and earnings per share declined from -$0.001 to -$0.0009.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to D+ from C on 8/20/2014 due to a significant decline in the efficiency index, growth index and volatility index. EBIT declined 16.35% from -$652.4 to -$545.7, net income declined 13.27% from -$650.3 to -$564, and earnings per share declined from -$0.001 to -$0.0009.
C
Hold
8/18/2014Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 8/18/2014 due to an increase in the total return index and volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 8/18/2014 due to an increase in the total return index and volatility index.
C
Hold
7/28/2014Downgrade
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 7/28/2014 due to a large decline in the volatility index.
Kraig Biocraft Laboratories, Inc. (KBLB) was downgraded to C- from C on 7/28/2014 due to a large decline in the volatility index.
C
Hold
5/16/2014Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 5/16/2014 due to an increase in the growth index, valuation index and solvency index. The quick ratio increased from 0.2 to 0.34.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C from C- on 5/16/2014 due to an increase in the growth index, valuation index and solvency index. The quick ratio increased from 0.2 to 0.34.
C
Hold
4/3/2014Upgraded
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C- from D+ on 4/3/2014 due to a substantial increase in the volatility index, valuation index and solvency index.
Kraig Biocraft Laboratories, Inc. (KBLB) was upgraded to C- from D+ on 4/3/2014 due to a substantial increase in the volatility index, valuation index and solvency index.
OTC PK
04/11/2025 3:59PM Eastern
Quotes delayed
